Overview

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients

Status:
Active, not recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced /Inflammatory HER2-positive Breast Cancer (ImmunHER)

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Oncologico Italiano di Ricerca Clinica

Collaborators:

Arithmos srl
Clirest s.r.l.
Mipharm SpA
Temas srl
University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit
University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology
University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione

Treatments:

Docetaxel
Pertuzumab
Trastuzumab